See “Risk Factors” beginning on page 6.Per ShareTotalInitial public offering price$$Underwriting discount$$Proceeds, before expenses, to Cutera, Inc.$$Proceeds, before expenses, to Selling Stockholders$$The underwriters have a 30-day option to purchase up to 465,000 additional shares of common stock from us to cover over-allotments, if any.Neither the Securities and Exchange Commission nor any state securities
worldwide leading provider of laser and other light-based systems to the aesthetic market by:•continuing to develop new products and applications;•increasing sales of existing products in the United States;•expanding our international presence;•broadening our customer base;•leveraging our installed base with sales of upgrades; and•acquiring complementary products, technologies and businesses.Our Products and ApplicationsOur CoolGlide family of products consists of a control console and one or more handpieces.
of Cutera, Inc. All other trademarks, tradenames and service marks appearing in this prospectus are the property of their respective owners.3Table of ContentsThe OfferingCommon stock offered:By us3,100,000 sharesBy Selling Stockholders432,000 sharesTotal3,532,000 sharesCommon stock outstanding after this offering10,088,114 sharesInitial public offering price$             per shareUse of proceedsWe intend to use the net proceeds received by us from this offering for sales and marketing operations, product research and development,
Incentive Plan; and•200,000 shares to be reserved for future issuance under our 2004 Employee Stock Purchase Plan.Unless otherwise indicated, all information in this prospectus assumes:•the underwriters do not exercise their over-allotment option;•the conversion of all outstanding shares of our preferred stock into 4,725,000 shares of our common stock; and•the adoption of our Amended and Restated Certificate of Incorporation and Bylaws.4Table of ContentsSummary Consolidated Financial DataThe following table presents summary historical and unaudited pro forma as adjusted financial data.
Financial Condition and Results of Operations.”Years Ended December 31,200120022003(in thousands, except per share data)Consolidated Statements of Operations Data:Net revenue(1)$19,328$28,327$39,088Cost of revenue(1)6,9419,99112,317Gross profit12,38718,33626,771Operating expenses:Sales and marketing5,6938,60213,792Research and development2,2212,9883,448General and administrative1,9635,4164,367Total operating expenses(1)9,87717,00621,607Income from operations2,5101,3305,164Interest and other income, net1718530Income before income taxes2,6811,4155,194Provision for income taxes(342)(755)(2,088)Net income$2,339$660$3,106Net income per share:Basic$1.58$0.36$1.47Diluted$0.27$0.07$0.35Weighted-average number of shares used in per share calculations:Basic1,4801,8102,106Diluted8,7318,8118,835Pro forma net income per share (unaudited):Basic$0.46Diluted$0.35Weighted-average number of shares used in pro forma per share calculations (unaudited):Basic6,794Diluted8,835(1)Includes the
following stock-based compensation charges:Net revenue$164$—$—Cost of revenue93234240Total operating expenses4959631,184$752$1,197$1,424As of December 31, 2003ActualPro FormaAs Adjusted(1)(in thousands)Consolidated Balance Sheet Data:Cash and cash equivalents$10,29051,835Working capital14,20555,750Total assets24,19865,743Redeemable convertible preferred stock7,372—Retained earnings4,1824,182Total stockholders’ equity7,87556,792(1)On a pro forma as adjusted basis to give effect to the automatic conversion of all outstanding shares of preferred stock into 4,725,000 shares of common stock
A number of additional factors, over which we have limited control, may contribute to fluctuations in our financial results, such as:•delays in introductions and acceptance of our future products;•delays in, or failure of, delivery of components by our suppliers;•introductions of new and improved products by competitors;•performance of our independent distributors;•increases in the length of our sales cycle;•fluctuations in foreign currency;•changes in our ability to obtain and maintain regulatory approvals; and•reductions in the efficiency of our manufacturing processes.In the event our actual revenue and operating results do not meet our forecasts for a particular period, the market price of our common stock may
successfully expand our product offerings, we must:•develop or acquire new products that either add to or significantly improve our current products;•convince our target customers that our new products or product upgrades would be an attractive revenue-generating addition to their practices;•sell our products to non-traditional customers;•protect our products with defensible intellectual property; and•satisfy and maintain all regulatory requirements for commercialization.Every year since 2000, we have introduced at least one new product and a corresponding upgrade to our existing products.
business, results of operations and financial condition.Intellectual property rights may not provide adequate protection for some or all of our products, which may permit third parties to compete against us more effectively.We rely on patent, copyright, trade secret and trademark laws, and
be unable to compete effectively and our business will be harmed.In addition, some of our current and potential competitors have significantly greater financial, research and development, manufacturing, and sales and marketing resources than we have.
subject to a number of risks, including:•difficulties in staffing and managing our foreign operations;•difficulties in penetrating markets in which our competitors’ products are more established;•reduced protection for intellectual property rights in some countries;•export restrictions, trade regulations and foreign tax laws;•fluctuating foreign currency exchange rates;•foreign certification and regulatory requirements;•lengthy payment cycles and difficulty in collecting accounts receivable;•customs clearance and shipping delays;•political and economic instability; and•preference for locally-produced products.If one or more of these risks were realized, it could require us to dedicate significant resources to remedy the situation, and if we are unsuccessful at
If we are unable to maintain adequate coverage, potential product liability claims would be paid out of cash reserves, harming our financial condition, operating results and profitability.10Table of ContentsIf we fail to obtain and maintain necessary U.S. Food and Drug Administration clearances for our
In addition, we will incur marketing costs in order to promote our new name, which will reduce our overall operating results in the near term.Risks Related to This OfferingOur common stock has not been publicly traded, and we expect that the
The market price for our common stock after this offering will be affected by a number of factors, including:•the announcement of new products or service enhancements by us or our competitors;•quarterly variations in our or our competitors’ results of operations;•announcements related to litigation;•changes in earnings estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts’ earning estimates;•developments in our industry; and•general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors.In addition, the stock prices of many companies in the medical device
will receive from the offering, we expect to use approximately:•$15.0 million for our sales and marketing operations; and•$5.0 million for product research and development.We intend to use the remainder of the net proceeds for general corporate purposes.
The historical results are not necessarily indicative of future operating results.Years Ended December 31,19992000200120022003(in thousands, except per share data)Consolidated Statements of Operations Data:Net revenue(1)$100$9,531$19,328$28,327$39,088Cost of revenue(1)4133,3656,9419,99112,317Gross profit (loss)(313)6,16612,38718,33626,771Operating expenses:Sales and marketing(1)7062,7945,6938,60213,792Research and development(1)1,3331,5392,2212,9883,448General and administrative(1)4199891,9635,4164,367Total operating expenses2,4585,3229,87717,00621,607Income (loss) from operations(2,771)8442,5101,3305,164Interest and other income, net571931718530Income (loss) before income taxes(2,714)1,0372,6811,4155,194Provision for income taxes——(342)(755)(2,088)Net income (loss)$(2,714)$1,037$2,339$660$3,106Net income (loss) per share:Basic$(3.04)$0.97$1.58$0.36$1.47Diluted$(3.04)$0.13$0.27$0.07$0.35Weighted-average number of shares used in per share calculations:Basic8921,0641,4801,8102,106Diluted8928,0088,7318,8118,835(1)Includes the following stock-based compensation charges:Net revenue$—$—$164$—$—Cost of revenue——93234240Sales and marketing——262366382Research and development——113287351General and administrative——120310451$—$—$752$1,197$1,424As of December 31,19992000200120022003(in thousands)Consolidated Balance Sheet Data:Cash and cash equivalents$4,184$3,562$6,354$8,276$10,290Working capital4,1804,7687,8548,89614,205Total assets4,9137,03812,47515,42624,198Redeemable convertible preferred stock7,2727,2727,2727,2727,372Retained earnings (deficit)(2,960)(1,923)4161,0764,182Total stockholders’ equity (deficit)(2,958)(1,918)1,2263,1067,87523Table of ContentsMANAGEMENT’S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONSThe following discussion of our financial condition and
statements as a result of many factors, including those discussed under “Risk Factors” and elsewhere in this prospectus.OverviewWe design, develop, manufacture and market the CoolGlide family of laser and other light-based products for aesthetic treatments.
other light-based procedures has resulted in an established and growing market for products and technologies that allow practitioners to perform these treatments.We currently sell, market and distribute our products in the United States through a direct sales force of 27